Fig. 2: CD8+ and CCT T cells exhibit specific antigens in NSCLC patients before and after anti-PD-1 therapy. | Nature Communications

Fig. 2: CD8+ and CCT T cells exhibit specific antigens in NSCLC patients before and after anti-PD-1 therapy.

From: Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Fig. 2

a Granzyme B and Tbet were remarkably upregulated in responders’ (n = 11) CD8+ T cells compared to non-responders’ (n = 14). b Similar trend of Granzyme B and Tbet were observed in CCT T cells, in which the CD27 level was significantly decreased in responders (n = 11) compared to non-responders (n = 14). c KLRG1 was remarkably increased as well in responders’ (n = 11) CCT cells compared to non-responders (n = 14). The percentages for each subpopulation are based on overall live CD45+ singlet cell counts. All p-values were calculated using two-sided t-tests. Two baseline samples (J015A and J024A) and 4 samples after treatment (J013B, J029B, and J024 B & C) as they failed the CyTOF QC test were excluded. R responder, NR non-responder. This box plots represent the interquartile range (IQR), with the horizontal line indicating the median. The whiskers extend to the farthest data point within a maximum of 1.5 × IQR.

Back to article page